Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BB-1701 by Bliss Biopharmaceutical (Hangzhou) for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase II for Human Epidermal Growth Factor Receptor...
BB-1701 by Bliss Biopharmaceutical (Hangzhou) for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According...
BB-1701 by Bliss Biopharmaceutical (Hangzhou) for Non-Small Cell Lung Cancer: Likelihood of Approval
BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase II for Non-Small Cell Lung Cancer. According...
BB-1701 by Bliss Biopharmaceutical (Hangzhou) for Gastric Cancer: Likelihood of Approval
BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase II for Gastric Cancer. According to GlobalData,...
BB-1705 by Bliss Biopharmaceutical (Hangzhou) for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
BB-1705 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According...
BB-1705 by Bliss Biopharmaceutical (Hangzhou) for Non-Small Cell Lung Cancer: Likelihood of Approval
BB-1705 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase I for Non-Small Cell Lung Cancer. According...
BB-1705 by Bliss Biopharmaceutical (Hangzhou) for Gastric Cancer: Likelihood of Approval
BB-1705 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase I for Gastric Cancer. According to GlobalData,...
BB-1705 by Bliss Biopharmaceutical (Hangzhou) for Head And Neck Cancer: Likelihood of Approval
BB-1705 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase I for Head And Neck Cancer. According...
BB-1701 by Bliss Biopharmaceutical (Hangzhou) for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer....
BB-1701 by Bliss Biopharmaceutical (Hangzhou) for Bladder Cancer: Likelihood of Approval
BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase II for Bladder Cancer. According to GlobalData,...
BB-1701 by Bliss Biopharmaceutical (Hangzhou) for Colon Cancer: Likelihood of Approval
BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase II for Colon Cancer. According to GlobalData,...
BB-1701 by Bliss Biopharmaceutical (Hangzhou) for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer....
BB-1701 by Bliss Biopharmaceutical (Hangzhou) for Bladder Cancer: Likelihood of Approval
BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase II for Bladder Cancer. According to GlobalData,...
BB-1701 by Bliss Biopharmaceutical (Hangzhou) for Colon Cancer: Likelihood of Approval
BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase II for Colon Cancer. According to GlobalData,...